Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
HCW Biologics Inc.
hcwbiologics.comAI Executive Summary
AI-powered analysis of 8-K filing content
HCW Biologics Inc. received a Nasdaq extension to regain compliance after failing to maintain the minimum $1 per share bid price requirement for 30 consecutive business days. The company must resolve this listing compliance issue within the granted extension period or face potential delisting.
Key Takeaways
HCW Biologics failed to maintain Nasdaq's minimum bid price of $1 per share for 30 consecutive business days, triggering a non-compliance notice
The company executed a 1-for-40 reverse stock split on April 11, 2025, which reset the compliance clock but did not prevent the subsequent price decline
2 more takeaways